Aetna denied your biologics? What to do next

Why Aetna (CVS Health) denies biologic and infusion therapy

Aetna, owned by CVS Health since 2018, runs commercial group plans, Medicare Advantage, and a large pharmacy benefit footprint via Caremark. GLP-1, specialty drug, and behavioral health denials are the highest-volume categories.

For biologic and infusion therapy specifically: Biologics such as adalimumab, infliximab, vedolizumab, ustekinumab, and rituximab are denied at prior authorization for step-therapy, missing labs, or diagnosis mismatch, and later for site of care or dose escalation. The appeal is a documentation exercise against the plan's own criteria.

The law that controls this appeal

Plan drug policies typically require a specific diagnosis, disease severity measures, a trial of conventional therapy (step therapy), tuberculosis and hepatitis screening, and prescriber specialty. Many states limit step therapy and require exception processes; federal rules for ACA plans require an exceptions process for non-formulary drugs (45 CFR 156.122(c)). Medicare Part B covers physician-administered biologics under medical necessity; Part D covers self-administered ones under formulary rules with a 60-day redetermination window (42 CFR 423.582). Criteria must be disclosed on request (29 CFR 2560.503-1(m)(8)).

What Aetna (CVS Health) denies for biologic and infusion therapy

The biologic and infusion therapy services most often denied:

First biologic for Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, or psoriasis
Switch to a second biologic after the first stops working
Dose escalation or interval shortening beyond the label
Infusion at a hospital outpatient department instead of home or a standalone center
Biosimilar substitution disputes

Why biologic and infusion therapy claims get denied

A typical Aetna (CVS Health) biologic and infusion therapy denial almost always cites one of these reasons. Each one maps to a specific rebuttal in the appeal:

Step therapy: conventional drugs (methotrexate, mesalamine, steroids) not tried or not documented
Disease activity scores or lab markers missing from the record
Diagnosis code does not match the labeled indication
TB or hepatitis B screening not on file
Plan prefers a different biologic or a biosimilar first

The Aetna (CVS Health) appeal process

Appeal levels: Internal level 1 (30 days standard / 72h urgent), then external IRO review (45 days standard).

Carrier timing: 180 days from denial for internal appeal; generally at least 4 months (120 days) from the final internal denial for federal external review (exact window varies by plan and state — check your denial letter).

Biologics timing: Untreated inflammatory disease supports an expedited appeal: decision within 72 hours. Internal appeal filing window: at least 180 days for commercial and employer plans; 65 days for Medicare Advantage; 60 days for Part D. External review: within 4 months of the final internal denial for ACA-covered plans (45 CFR 147.136).

What we know about Aetna (CVS Health): Aetna's internal appeals respond well to peer-to-peer review requests filed alongside the written appeal.

Common Aetna (CVS Health) denial patterns for biologic and infusion therapy

GLP-1 / Wegovy denials citing BMI. Aetna denies most weight-loss GLP-1 prescriptions citing BMI thresholds or 'lifestyle modification first' criteria. When a patient has documented comorbidities (such as type 2 diabetes) and the treating clinician determines a diabetes-indicated GLP-1 is medically appropriate, an appeal built on that documented clinical picture is often reversed quickly — the medication and indication remain the clinician's decision, never a path chosen simply to obtain coverage.
Caremark formulary denials. Aetna's pharmacy benefit (Caremark) issues formulary denials separate from medical benefit denials. Each requires its own appeal track, confusing the two costs weeks.
Internal appeal then external review. Aetna's first appeal is internal and is generally filed within 180 days of the denial. After a final internal denial, external review by an Independent Review Organization (IRO) is a separately strong reversal lane; under the federal ACA standard members generally have at least 4 months (120 days) to request it, though the exact window varies by plan and state — confirm the deadline printed on your denial letter.

How to win your Aetna (CVS Health) biologic and infusion therapy appeal

Strategy for biologic and infusion therapy: Get the plan's drug policy and match every criterion to a page in the chart: diagnosis, severity score, prior drugs with dates and outcomes, screening labs, prescriber specialty. Where step therapy is the reason, use the plan's exception process and, where applicable, the state step-therapy law that requires an override when the required drug was tried, is contraindicated, or is expected to be ineffective. For a switch after loss of response, document the objective loss of response. Ask for a peer-to-peer with a reviewer in the same specialty.

Filed against Aetna (CVS Health), that strategy rides on this procedural spine:

Procedural-rights anchor. Every Aetna (CVS Health) denial triggers ERISA § 503 or 45 C.F.R. § 147.136 procedural rights. The cover letter invokes these in the opening paragraph to lock the timeline and force criteria disclosure.
Criteria-disclosure demand. Aetna (CVS Health) frequently denies on "not medically necessary" without disclosing the clinical criteria applied. Once disclosed, those criteria become the rebuttal map.
Controlling-standard citation. Plan drug policies typically require a specific diagnosis, disease severity measures, a trial of conventional therapy (step therapy), tuberculosis and hepatitis screening, and prescriber specialty. Many states limit step therapy and require exception processes; federal rules for ACA plans require an exceptions process for non-formulary drugs (45 CFR 156.122(c)). Medicare Part B covers physician-administered biologics under medical necessity; Part D covers self-administered ones under formulary rules with a 60-day redetermination window (42 CFR 423.582). Criteria must be disclosed on request (29 CFR 2560.503-1(m)(8)).
Treating-provider attestation. A letter from the treating physician addressing each criterion in Aetna (CVS Health)'s own policy language. This is the single strongest evidentiary element.
Requested action. A specific demand to reverse the biologic and infusion therapy denial and approve the service, not a general "please reconsider."

Documents you'll need for your Aetna (CVS Health) biologic and infusion therapy appeal

The denial letter with the criterion or policy cited
Specialist's notes with diagnosis and disease-activity measures
Prior medication history with dates, doses, and outcomes
TB, hepatitis, and other screening results
The plan's drug policy and formulary exception form

What a biologic and infusion therapy appeal can recover

Typical recovery for biologic and infusion therapy cases runs Biologics are priced in the thousands of dollars per dose; a denied year of therapy is commonly a five-figure sum at billed charges.. The exact figure depends on the specific service and your plan's contracted rates.

Aetna (CVS Health) biologic and infusion therapy appeals: frequently asked questions

Aetna (CVS Health) wants me to fail a cheaper drug first. Do I have to?

Not always. Plans must have an exception process, and many states require an override when the required drug was already tried, is contraindicated, or is expected to be ineffective. The prescriber's letter should say which of those applies and why.

Why was my biologic denied when my doctor prescribed it?

Most denials are documentation gaps: a missing severity score, an undocumented prior drug, or a screening lab not on file. The plan's policy tells you exactly which item is missing; request it.

Aetna (CVS Health) moved my infusions out of the hospital. Can I appeal the site of care?

Yes. Site-of-care denials are appealable. The record needs to show why the hospital setting is medically required, for example prior infusion reactions or complex comorbidities.

Is a biosimilar the same drug?

A biosimilar is highly similar to the reference biologic with no clinically meaningful difference, per FDA. Plans may prefer one. If a switch caused loss of response or an adverse reaction, that history is the basis for an exception.

What Apellica does for Aetna (CVS Health) biologic and infusion therapy appeals

We file appeals against Aetna (CVS Health) specifically configured to its internal review process. Every biologic and infusion therapy appeal embeds the criteria-disclosure demand, the procedural-rights anchor, the controlling-standard citation above, treating-provider attestation language, and the peer-reviewed evidence relevant to the denied service.

Cost: $0 upfront. We work on contingency for Aetna (CVS Health) appeals, if the appeal succeeds, we collect a percentage of the recovered claim value. If it fails, you owe nothing.

Start your Aetna (CVS Health) biologic and infusion therapy appeal

Submit a 2-minute intake. A senior reviewer responds within one business day with the specific appeal strategy for your case.

Start free appeal review →

Aetna (CVS Health) denied your biologic and infusion therapy? Here is what to do next